AM
NBIX icon

AGF Management’s Neurocrine Biosciences NBIX Stock Holding History

AGF Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,332
Closed -$258K – 701
2025
Q1 		$258K Sell
2,332
-2,301
-50% -$291K ﹤0.01% 639
2024
Q4 		$632K Buy
+4,633
New +$573K ﹤0.01% 603
2024
Q2 		– Sell
-16,637
Closed -$2.29M – 737
2024
Q1 		$2.29M Sell
16,637
-8,209
-33% -$1.12M 0.01% 448
2023
Q4 		$3.27M Sell
24,846
-3,669
-13% -$422K 0.02% 325
2023
Q3 		$3.21M Sell
28,515
-9,084
-24% -$957K 0.02% 313
2023
Q2 		$3.55M Buy
37,599
+3,197
+9% +$312K 0.03% 366
2023
Q1 		$3.48M Buy
34,402
+7,166
+26% +$746K 0.02% 336
2022
Q4 		$3.25M Buy
+27,236
New +$3.19M 0.02% 411

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AGF Management's NBIX Position: Q2 2025 in Review

AGF Management sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 2,332 shares — an estimated $258K sold.

AGF Management first reported a position in NBIX in Q4 2022 and held it in 8 quarters. The position peaked at $3.55M in Q2 2023. 585 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

  • AGF Management reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
  • AGF Management sold 2,332 Neurocrine Biosciences shares in Q2 2025, an estimated $258K.
  • AGF Management first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 8 quarters.
  • AGF Management's Neurocrine Biosciences position peaked at $3.55M in Q2 2023.
  • 585 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on AGF Management's 13F filing for Q2 2025, filed 6 Aug 2025.